European Journal of Pediatrics

, Volume 152, Issue 9, pp 717–720 | Cite as

Reduction of bone density: An effect of gonadotropin releasing hormone analogue treatment in central precocious puberty

  • G. Saggese
  • S. Bertelloni
  • G. I. Baroncelli
  • R. Battini
  • G. Franchi


Gonadal steroids drive the significant bone mineral increase that occurs at puberty. Oestrogen deprivation in women results in bone loss. We investigated bone mineralization by single photon absorptiometry in girls with central precocious puberty (n=13, age 3.8–8.5 years) before and during 1 year of treatment with gonadotropin releasing hormone analogue (GnRH-a=longacting D-Trp6-GnRH, 60 μg i.m. every 28 days). Before GnRH-a therapy, bone mineral density (BMD) was significantly higher in patients than in ten control girls matched for chronological age (patients 0.575±0.097 g/cm2, controls 0.433±0.049 g/cm2,P<0.001). Patient BMD was not significantly different from that of ten control girls matched according to patient bone age (0.550±0.046 g/cm2,P=NS). During GnRH-a treatment, pituitary-gonadal axis was suppressed and patient BMD significantly decreased (6 months: −6.0%,P<0.002 vs baseline; 12 months: −8.0%,P<0.001 vs baseline). We conclade that in girls with precocious puberty the activation of gonadal steroid secretion induces an increase in bone mineralization and that oestrogen deprivation by GnRH-a treatment caused a significant decrease in BMD.

Key words

Central precocious puberty Gonadotropin-releasing hormone analogue Bone mineralization Bone mineral density 



bone mineral density


body mass index


central precocious puberty


gonadotropin releasing hormone analogue


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aksnes L, Aarskog D (1982) Plasma concentrations of vitamin D metabolites in puberty: effect of sexual maturation and implication for growth. J Clin Endocrinol Metab 62:94–101Google Scholar
  2. 2.
    Boepple PA, Mansfield MJ, Wierman ME, Rudlin CR, Bode HH, Crigler JF, Craford JD, Crowley WF (1986) Use of a potent, long-acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev 7:24–33PubMedGoogle Scholar
  3. 3.
    Cann CE, Genant HK, Ettinger B, Gordon GS (1980) Spinal mineral loss in oophorectomized women: determination by quantitative computed tomography. JAMA 244:2056–2057CrossRefPubMedGoogle Scholar
  4. 4.
    Devogelaer J-P, Nagant De Deuxchaisnes, Donnez J, Thomas K (1987) LHRH analogues and bone loss. Lancet I:1498CrossRefGoogle Scholar
  5. 5.
    Di Martino-Nardi J, Wu R, Fishman K, Saenger P (1991) The effect of long-acting analog of luteinizing hormone releasing hormone on growth hormone secretory dynamics in children with precocious puberty. J Clin Endocrinol Metab 73:902–906PubMedGoogle Scholar
  6. 6.
    Dodin S, Lemay A, Maheux R, Dumont M, Turcot-Lemay (1991) Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol 77:410–415PubMedGoogle Scholar
  7. 7.
    Eriksen EF, Colvard DS, Berg NJ (1988) Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241:84–86PubMedGoogle Scholar
  8. 8.
    Ernst M, Schmidt C, Froesh ER (1988) Enhanced osteoblast proliferation and collagen gene expression by estradiol. Proc Natl Acad Sci USA 85:2307–2309PubMedGoogle Scholar
  9. 9.
    Finkelstein JS, Neer RM, Biller BMK, Crawford JD, Klibanski A (1992) Osteopenia in men with a history of delayed puberty. N Engl J Med 326:600–604PubMedGoogle Scholar
  10. 10.
    Gilsanz V, Gibbens DT, Roe TF, Carlson M, Senac MO, Boechat MI, Huang HK, Schulz EE, Libanati CR, Cann CC (1988) Vertebral bone density in children: effect of puberty. Radiology 166:847–850PubMedGoogle Scholar
  11. 11.
    Glastre C, Braillon P, David L, Cochat P, Meunier PJ, Delmas PD (1990) Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlation with growth parameters. J Clin Endocrinol Metab 70:1330–1333PubMedGoogle Scholar
  12. 12.
    Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of hand and wrist, 2nd edn. Stanford University Press, StanfordGoogle Scholar
  13. 13.
    Krabbe S, Transbol I, Christiansen C (1982) Bone mineral homeostasis, bone growth, and mineralization during years of pubertal growth: a unifying concept. Arch Dis Child 57:359–363PubMedGoogle Scholar
  14. 14.
    Krabbe S, Gotfredsen A, Christiansen C (1984) Relationship between local and total bone mineral in normal pubertal boys. Eur J Pediatr 143:149–151CrossRefPubMedGoogle Scholar
  15. 15.
    Matta WH, Shaw RW, Hesp R, Evans R (1988) Reversible trabecular bone density loss following induced hypooestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol 29:45–51Google Scholar
  16. 16.
    Oostdijk W, Hummelink R, Odink RJK, Partsch CJ, Drop SLS, Lorenz F, Sippell WG, Velde EA van der, Schultheiss H (1990) Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist. Eur J Pediatr 149:308–313PubMedGoogle Scholar
  17. 17.
    Ott SM (1990) Editorial: attainment of peak bone mass. J Clin Endocrinol Metab 71:1082A-1082CPubMedGoogle Scholar
  18. 18.
    Perren TJ, Clayton RN, Blackedge G (1986) Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (Zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer. Cancer Chemother Pharmacol 18:39–43CrossRefPubMedGoogle Scholar
  19. 19.
    Riggs LB, Melton III LJ (1986) Involutional osteoporosis. N Engl J Med 314:1676–1686PubMedGoogle Scholar
  20. 20.
    Roger M, Chaussain JL, Berlier P, Bost M, Canlorbe P, Colle M, Francoise R, Garandeau P, Lahlou N, Morel Y, Shally AV (1986) Long term treatment of male and female precocious puberty by administration of long-acting preparation ofd-Trp6-luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab 62:670–677PubMedGoogle Scholar
  21. 21.
    Saggese G, Federico G, Ghirri P, Cipriani J, Bertelloni S, Baroncelli GI (1986) Densitometria ossea in età pediatrica. Valori Normali tra 2 e 19 anni. Primi dati italiani. Minerva Pediatr 38:545–551PubMedGoogle Scholar
  22. 22.
    Saggese G, Bertelloni S, Baroncelli GI (1990) Bone mineralization and calciotropic hormones in children with hyperthyroidism. Effects of methimazole therapy. J Endocrinol Invest 13: 587–592PubMedGoogle Scholar
  23. 23.
    Saggese G, Bertelloni S, Baroncelli GI, Pardi D, Cinquanta L (1991) Bone loss during gonadotropin-releasing hormone agonist treatment in girls with true precocious puberty is not due to an impairment of calcitonin secretion. J Endocrinol Invest 14:231–236PubMedGoogle Scholar
  24. 24.
    Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G (1993) Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 122:37–45PubMedGoogle Scholar
  25. 25.
    Saggese G, Bertelloni S, Baroncelli GI, Di Nero G, Battini R (1993) Growth velocity and serum aminoterminal propetide of type III procollagen in precocious puberty during gonadotropin-releasing hormone analogue treatment. Acta Paediatr 82: 261–266PubMedGoogle Scholar
  26. 26.
    Shore RM, Chesney RW, Mazess RB, Rose PG, Bargmann GJ (1980) Bone mineral status in growth hormone deficiency. J Pediatr 96:393–396PubMedGoogle Scholar
  27. 27.
    Stanhope R, Pringle PJ, Brooke CGD (1988) Growth, growth hormone, and sex steroid secretion in girls with central precocious puberty treated with a gonadotropin release hormone (GnRH) analogue. Acta Paediatr Scand 77:525–530PubMedGoogle Scholar
  28. 28.
    Tummon IS, Radwanska E, Ali A, Binor Z, Pepping ME, Dmowski WP (1988) Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertil Steril 49:792–796PubMedGoogle Scholar
  29. 29.
    Waibel-Treber S, Minne HW, Scharla SH, Bremen T, Ziegler R, Leyendecker G (1989) Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma. Hum Reprod 4:384–388PubMedGoogle Scholar
  30. 30.
    Wheeler MD, Styne DM (1990) Diagnosis and management of precocious puberty. Pediatr Clin North Am 37:1255–1271PubMedGoogle Scholar
  31. 31.
    Zachmann M (1992) Interrelations between growth hormone and sex hormones. Physiology and therapeutic consequences. The Third hGH Symposium Sorrento 1992, May 15–16, Sorrento, ItalyGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • G. Saggese
    • 1
  • S. Bertelloni
    • 1
  • G. I. Baroncelli
    • 1
  • R. Battini
    • 1
  • G. Franchi
    • 1
  1. 1.Endocrine Unit, Chair of Preventive Paediatrics, Department of PaediatricsUniversity of PisaPisaItaly

Personalised recommendations